Home > Boards > US Listed > Electronics and components > Ameri Holdings Inc. (AMRH)

AMERI Holdings, Inc. (NASDAQ: AMRH) (“Ameri”) today announced

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Hawkeye_tt Member Profile
 
Followed By 15
Posts 4,544
Boards Moderated 1
Alias Born 06/27/03
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 1/15/2021 4:16:53 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 1/13/2021 5:28:49 PM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 1/13/2021 5:25:51 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 1/12/2021 4:42:59 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/12/2021 9:11:22 AM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 1/11/2021 7:43:28 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 1/8/2021 4:56:36 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 1/8/2021 4:52:44 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 1/8/2021 4:52:18 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 1/8/2021 4:47:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/6/2021 5:11:52 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/6/2021 5:11:04 PM
Ameri Holdings Completes Spin-Off and Tender Offer, Changes Name to Enveric Biosciences and Begins Trading on the Nasdaq Unde... PR Newswire (US) - 12/31/2020 8:21:00 AM
AMERI Holdings Announces 1-for-4 Reverse Stock Split PR Newswire (US) - 12/30/2020 12:59:00 PM
AMERI Holdings' Stockholders Approve All Proposals To Complete Tender Offer For Jay Pharma Shares PR Newswire (US) - 12/29/2020 10:10:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/29/2020 10:07:45 AM
Registration Pursuant to Securities Act Rule 462(b) of up to an Additional 20% of Securities for an Offering That Was Registe... Edgar (US Regulatory) - 12/28/2020 5:31:24 PM
Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) Edgar (US Regulatory) - 12/23/2020 5:28:29 PM
AMERI Holdings Adjourns Special Stockholder Meeting To December 29th PR Newswire (US) - 12/23/2020 12:40:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/18/2020 5:43:37 PM
Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) Edgar (US Regulatory) - 12/18/2020 5:43:33 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/15/2020 4:05:59 PM
AMERI Holdings Announces S-4 Has Been Declared Effective PR Newswire (US) - 11/16/2020 9:26:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/16/2020 6:38:42 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 11/13/2020 2:49:18 PM
Hawkeye_tt   Monday, 01/13/20 09:21:29 AM
Re: None
Post # of 645 
AMERI Holdings, Inc. (NASDAQ: AMRH) (“Ameri”) today announced it entered into an amalgamation agreement (the “Amalgamation Agreement”) with Jay Pharma Inc. (“Jay Pharma”), a Canadian company dedicated to developing innovative, evidence-based cannabinoid products and combination therapies to address unmet needs in cancer care, pursuant to which the shareholders of Jay Pharma will become the majority holders of Ameri’s outstanding stock by way of an amalgamation (the “Amalgamation”). In connection with the Amalgamation, Ameri will spin-off its existing IT services business to a private entity founded by Ameri management in partnership with Ameri’s current Series A Preferred Equity Holders (the “Spin-Off,” and collectively, with the Amalgamation, the “Transactions”). The Transactions are expected to close in the first half of 2020, subject to Ameri shareholder approval, approval of the Nasdaq Stock Market, and other customary closing conditions.
“We are excited about the Jay Pharma business and believe that it is a great opportunity that will maximize shareholder value,” said Dev Nidhi, Executive Chairman of Ameri.

On a pro forma basis and based upon the number of shares of Ameri common stock to be issued in the Amalgamation, current Ameri shareholders will own approximately 16% of the combined company and current Jay Pharma shareholders will own approximately 84% of the combined company. The Boards of Directors of both Ameri and Jay Pharma have unanimously approved the transaction.

Jay Pharma is primarily focused on developing over-the-counter cannabinoid-based palliative and wellness products to address the side effects of cancer and cancer treatment, including skin reactions, pain, nausea, and anxiety. Jay Pharma holds the exclusive rights to Israel-based Tikun Olam Ltd.’s (“Tikun Olam”) proprietary cannabinoid genetics and data for oncology, including for the development of over-the-counter and pharmaceutical products. Tikun Olam has amassed one of the world’s largest patient treatment databases in the field of medical cannabis, with over 20,000 patient records noting strains used and symptoms treated. Use of Tikun Olam strains were analyzed in 2,970 cancer patients seeking assistance with sleep problems, pain, nausea, and lack of appetite (Bar-lev Schleider, Eur J Intern Med, 2018); treatment was found to be a well-tolerated, effective, and safe option to help patients cope with the malignancy related symptoms. Jay Pharma plans to bring leading oncology clinicians and researchers, together with academic and industry partners to enhance clinically proven products to patients. In addition, Jay Pharma has an experienced management team led by Dave Johnson who will assume the Chairman & CEO role upon the closing of the Transactions.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences